Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
As the biotech markets turned bullish the sector’s ups and downs continued.